Clinical Trial Update: Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) [Phase 3]

View source ↗

Summary

A Phase 3 trial (ELITE-ACT) is evaluating early infusion of eptinezumab for acute post-traumatic headaches; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Headache

Drugs mentioned

• VYEPTI (eptinezumab)

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Post Traumatic Headache | Phase 3 | Status: NOT_YET_RECRUITING